108 related articles for article (PubMed ID: 15931189)
1. Molecular medicine: lost in translation.
Ainsworth C
Nature; 2005 Jun; 435(7042):556-8. PubMed ID: 15931189
[No Abstract] [Full Text] [Related]
2. Hereditary leukodystrophies without identified mutations.
Robitaille Y
J Neurol Sci; 2005 Feb; 228(2):208-9. PubMed ID: 15694209
[No Abstract] [Full Text] [Related]
3. Progressive megalencephaly due to specific EIF2Bepsilon mutations in two unrelated families.
Passemard S; Gelot A; Fogli A; N'Guyen S; Barnerias C; Niel F; Doummar D; Arbues AS; Mignot C; de Villemeur TB; Ponsot G; Boespflug-Tanguy O; Rodriguez D
Neurology; 2007 Jul; 69(4):400-2. PubMed ID: 17646634
[No Abstract] [Full Text] [Related]
4. Genetic and clinical heterogeneity in eIF2B-related disorder.
Maletkovic J; Schiffmann R; Gorospe JR; Gordon ES; Mintz M; Hoffman EP; Alper G; Lynch DR; Singhal BS; Harding C; Amartino H; Brown CM; Chan A; Renaud D; Geraghty M; Jensen L; Senbil N; Kadom N; Nazarian J; Yuanjian Feng ; Zuyi Wang ; Hartka T; Morizono H; Vanderver A
J Child Neurol; 2008 Feb; 23(2):205-15. PubMed ID: 18263758
[TBL] [Abstract][Full Text] [Related]
5. The large spectrum of eIF2B-related diseases.
Fogli A; Boespflug-Tanguy O
Biochem Soc Trans; 2006 Feb; 34(Pt 1):22-9. PubMed ID: 16246171
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of mutations for the diagnosis of vanishing white matter disease.
Scali O; Di Perri C; Federico A
Neurol Sci; 2006 Sep; 27(4):271-7. PubMed ID: 16998732
[TBL] [Abstract][Full Text] [Related]
7. Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients.
Fogli A; Schiffmann R; Hugendubler L; Combes P; Bertini E; Rodriguez D; Kimball SR; Boespflug-Tanguy O
Eur J Hum Genet; 2004 Jul; 12(7):561-6. PubMed ID: 15054402
[TBL] [Abstract][Full Text] [Related]
8. Novel mutation in EIF2B gene in a case of adult-onset leukoencephalopathy with vanishing white matter.
Matsui M; Mizutani K; Ohtake H; Miki Y; Ishizu K; Fukuyama H; Shimohata T; Onodera O; Nishizawa M; Takayama Y; Shibasaki H
Eur Neurol; 2007; 57(1):57-8. PubMed ID: 17119336
[No Abstract] [Full Text] [Related]
9. The ovarioleukodystrophy.
Mathis S; Scheper GC; Baumann N; Petit E; Gil R; van der Knaap MS; Neau JP
Clin Neurol Neurosurg; 2008 Dec; 110(10):1035-7. PubMed ID: 18678442
[TBL] [Abstract][Full Text] [Related]
10. Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases.
Labauge P; Horzinski L; Ayrignac X; Blanc P; Vukusic S; Rodriguez D; Mauguiere F; Peter L; Goizet C; Bouhour F; Denier C; Confavreux C; Obadia M; Blanc F; de Sèze J; Fogli A; Boespflug-Tanguy O
Brain; 2009 Aug; 132(Pt 8):2161-9. PubMed ID: 19625339
[TBL] [Abstract][Full Text] [Related]
11. Identification of ten novel mutations in patients with eIF2B-related disorders.
Ohlenbusch A; Henneke M; Brockmann K; Goerg M; Hanefeld F; Kohlschütter A; Gärtner J
Hum Mutat; 2005 Apr; 25(4):411. PubMed ID: 15776425
[TBL] [Abstract][Full Text] [Related]
12. [Eukaryotic translation and nuclear events].
Imataka H
Tanpakushitsu Kakusan Koso; 2004 Jul; 49(9):1296-301. PubMed ID: 15242056
[No Abstract] [Full Text] [Related]
13. Dominant form of vanishing white matter-like leukoencephalopathy.
Labauge P; Fogli A; Castelnovo G; Le Bayon A; Horzinski L; Nicoli F; Cozzone P; Pagès M; Briere C; Marty-Double C; Delhaume O; Gelot A; Boespflug-Tanguy O; Rodriguez D
Ann Neurol; 2005 Oct; 58(4):634-9. PubMed ID: 16047349
[TBL] [Abstract][Full Text] [Related]
14. eIF2B, a mediator of general and gene-specific translational control.
Pavitt GD
Biochem Soc Trans; 2005 Dec; 33(Pt 6):1487-92. PubMed ID: 16246152
[TBL] [Abstract][Full Text] [Related]
15. Vanishing white matter disease: the first reported chinese patient.
Wong SS; Luk DC; Wong VC; Scheper GC; van der Knaap MS
J Child Neurol; 2008 Jun; 23(6):710-4. PubMed ID: 18539998
[TBL] [Abstract][Full Text] [Related]
16. Lost in translation.
Julier C
Nat Genet; 2001 Dec; 29(4):358-9. PubMed ID: 11726916
[No Abstract] [Full Text] [Related]
17. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter.
Leegwater PA; Vermeulen G; Könst AA; Naidu S; Mulders J; Visser A; Kersbergen P; Mobach D; Fonds D; van Berkel CG; Lemmers RJ; Frants RR; Oudejans CB; Schutgens RB; Pronk JC; van der Knaap MS
Nat Genet; 2001 Dec; 29(4):383-8. PubMed ID: 11704758
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic initiation factor 2B and its role in alterations in mRNA translation that occur under a number of pathophysiological and physiological conditions.
Kubica N; Jefferson LS; Kimball SR
Prog Nucleic Acid Res Mol Biol; 2006; 81():271-96. PubMed ID: 16891174
[No Abstract] [Full Text] [Related]
19. Exon deletion in the non-catalytic domain of eIF2Bepsilon due to a splice site mutation leads to infantile forms of CACH/VWM with severe decrease of eIF2B GEF activity.
Horzinski L; Gonthier C; Rodriguez D; Scherer C; Boespflug-Tanguy O; Fogli A
Ann Hum Genet; 2008 May; 72(Pt 3):410-5. PubMed ID: 18294360
[TBL] [Abstract][Full Text] [Related]
20. Vanishing white matter disease associated with progressive macrocephaly.
Pineda M; R-Palmero A; Baquero M; O'Callaghan M; Aracil A; van der Knaap M; Scheper GC
Neuropediatrics; 2008 Feb; 39(1):29-32. PubMed ID: 18504679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
